阿糖胞苷联合地西他滨治疗急性髓系白血病患者的有效性及对外周血T淋巴细胞亚群的影响  

Efficacy of Cytarabine Combined with Decitabine in the Treatment of Acute Myeloid Leukemia and Its Effect on Peripheral Blood T Lymphocyte Subsets

作　　者：崔文婷[1] 胡苏[1] 黄燕[1] CUI Wenting;HU Su;HUANG Yan(Jiujiang First People’s Hospital,Jiujiang 343100,China;不详)

机构地区：[1]江西省九江市第一人民医院,江西九江343100

出　　处：《中国医学创新》2021年第21期1-5,共5页Medical Innovation of China

摘　　要：目的:探讨阿糖胞苷联合地西他滨治疗急性髓系白血病患者的有效性及对患者外周血T淋巴细胞亚群的影响。方法:选取2015年1月-2020年12月本院收治的70例急性髓系白血病患者,根据随机数字表法分为对照组和研究组,每组35例。对照组采用米托蒽醌联合阿糖胞苷治疗,研究组采用阿糖胞苷联合地西他滨治疗。比较两组疗效、不良反应发生情况及治疗前后的外周血T淋巴细胞亚群水平(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、血清酶水平[乳酸脱氢酶(LDH)、谷氨酰转肽酶(GGT)、碱性磷酸酶(ALP)、羟丁酸脱氢酶(HBDH)]。结果:研究组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组LDH、GGT、ALP、HBDH比较,差异均无统计学意义(P>0.05);治疗后,两组LDH、GGT、ALP、HBDH均低于治疗前,且研究组均低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比较,差异均无统计学意义(P>0.05);治疗后,两组CD8^(+)均低于治疗前,CD4^(+)、CD4^(+)/CD8^(+)均高于治疗前,研究组CD8^(+)低于对照组,CD4^(+)和CD4^(+)/CD8^(+)均高于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:阿糖胞苷与地西他滨联合的方案对急性髓系白血病患者进行治疗,可提高疗效,改善免疫功能及血清酶水平,无明显不良反应,安全可靠,值得推广应用。Objective:To investigate the efficacy of Cytarabine combined with Decitabine in the treatment of acute myeloid leukemia and its effect on peripheral blood T lymphocyte subsets.Method:A total of 70 patients with acute myeloid leukemia admitted to our hospital from January 2015 to December 2020 were selected,and they were randomly divided into control group and study group according to number table method,35 patients in each group.The control group was treated with Mitoxantrone combined with Cytarabine,and the study group was treated with Cytarabine combined with Decitabine.The efficacy,occurrence of ADR were compared between two groups,the peripheral blood T lymphocyte subsets (CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),serum enzyme levels[lactate dehydrogenase (LDH),glutamyl transpeptidase (GGT),alkaline phosphatase (ALP),hydroxybutyrate dehydrogenase (HBDH)]before and after treatment were compared between two groups.Result:The total effective rate of the study group was higher than that of the control group,and the difference was statistically significant (P<0.05).Before treatment,there were no significant differences in LDH,GGT,ALP and HBDH between two groups (P>0.05);after treatment,LDH,GGT,ALP and HBDH of both groups were lower than those of before treatment,and those of the study group were lower than those of the control group,the differences were statistically significant (P<0.05).Before treatment,there were no significant differences in CD4^(+),CD8^(+) and CD4^(+)/CD8^(+) between two groups (P>0.05);after treatment,CD8^(+) of both groups were lower than those of before treatment,CD4^(+) and CD4^(+)/CD8^(+) of both groups were higher than those of before treatment,CD8^(+) of the study group was lower than that of the control group,CD4^(+) and CD4^(+)/CD8^(+) of the study group were higher than those of the control group,the differences were statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between two groups (P>0.05).Conclusion:The combination of Cytarabine

关 键 词：急性髓系白血病 阿糖胞苷 地西他滨 T淋巴细胞亚群 血清酶 

分 类 号：R733.71[医药卫生—肿瘤]